Literature DB >> 28349408

Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Verena Staedtke1,2, Ren-Yuan Bai3, Jaishri O'Neill Blakeley4,5,6.   

Abstract

The RASopathy neurofibromatosis 1 is an autosomal dominant hereditary cancer syndrome that represents a major risk for the development of malignancies, particularly malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are unique sarcomas that originate from the peripheral nerve and represent the only primary cancer of the peripheral nervous system. To date, surgery is the only treatment modality proven to have survival benefit for MPNSTs and even when maximal surgery is feasible, these tumors are rarely curable, despite the use of chemotherapy and radiation. In this review, we discuss the current state-of-the-art treatments for MPNSTs, latest therapeutic developments, and critical aspects of the underlying molecular and pathophysiology that appear promising for therapeutic developments in the future. In particular, we discuss the specific elements of cancer in the peripheral nerve and how that may impel development of unique therapies for this form of sarcoma.

Entities:  

Keywords:  Chemoprevention; Malignant peripheral nerve sheath tumor; Malignant transformation; Neurofibromatosis; Sarcoma; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28349408      PMCID: PMC5398990          DOI: 10.1007/s13311-017-0518-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  65 in total

1.  18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).

Authors:  Holly Meany; Eva Dombi; James Reynolds; Millie Whatley; Ambereen Kurwa; Maria Tsokos; Wanda Salzer; Andrea Gillespie; Andrea Baldwin; Joanne Derdak; Brigitte Widemann
Journal:  Pediatr Blood Cancer       Date:  2012-05-29       Impact factor: 3.167

2.  Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis.

Authors:  Benjamin C Ling; Jianqiang Wu; Shyra J Miller; Kelly R Monk; Rania Shamekh; Tilat A Rizvi; Gabrielle Decourten-Myers; Kristine S Vogel; Jeffrey E DeClue; Nancy Ratner
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

3.  Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience.

Authors:  Chee-Chee H Stucky; Kevin N Johnson; Richard J Gray; Barbara A Pockaj; Idris T Ocal; Peter S Rose; Nabil Wasif
Journal:  Ann Surg Oncol       Date:  2011-08-23       Impact factor: 5.344

4.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

5.  The genetic aspects of neurofibromatosis.

Authors:  J C Carey; B J Baty; J P Johnson; T Morrison; M Skolnick; J Kivlin
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

6.  Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.

Authors:  Mikiko Aoki; Kazuki Nabeshima; Kaori Koga; Makoto Hamasaki; Junji Suzumiya; Kazuo Tamura; Hiroshi Iwasaki
Journal:  Lab Invest       Date:  2007-06-11       Impact factor: 5.662

7.  Remission of disseminated cancer after systemic oncolytic virotherapy.

Authors:  Stephen J Russell; Mark J Federspiel; Kah-Whye Peng; Caili Tong; David Dingli; William G Morice; Val Lowe; Michael K O'Connor; Robert A Kyle; Nelson Leung; Francis K Buadi; S Vincent Rajkumar; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2014-05-14       Impact factor: 7.616

8.  Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.

Authors:  Verena Staedtke; Ren-Yuan Bai; Weiyun Sun; Judy Huang; Kathleen Kazuko Kibler; Betty M Tyler; Gary L Gallia; Kenneth Kinzler; Bert Vogelstein; Shibin Zhou; Gregory J Riggins
Journal:  Oncotarget       Date:  2015-03-20

9.  Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.

Authors:  Séverine Tabone-Eglinger; Radislav Bahleda; Jean-François Côté; Philippe Terrier; Dominique Vidaud; Anne Cayre; Alain Beauchet; Nathalie Théou-Anton; Marie-José Terrier-Lacombe; Antoinette Lemoine; Frédérique Penault-Llorca; Axel Le Cesne; Jean-François Emile
Journal:  Sarcoma       Date:  2008

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  12 in total

1.  The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Liang Zhao; Ying Wu; Vijayabhaskar Veeravalli; Jesse Alt; Joanna Marie H Aguilar; Ranjeet P Dash; Jenny Lam; Lukáš Tenora; Chabely Rodriguez; Michael T Nedelcovych; Cory Brayton; Pavel Majer; Jaishri O Blakeley; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

2.  Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.

Authors:  Jianman Guo; Katherine E Chaney; Kwangmin Choi; Gabriela Witek; Ami V Patel; Hong Xie; Danny Lin; Kanupriya Whig; Yao Xiong; David C Schultz; Nancy Ratner; Jeffrey Field
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

3.  Neonatal hyperinsulinemic hypoglycemia: case report of kabuki syndrome due to a novel KMT2D splicing-site mutation.

Authors:  Ettore Piro; Ingrid Anne Mandy Schierz; Vincenzo Antona; Maria Pia Pappalardo; Mario Giuffrè; Gregorio Serra; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2020-09-18       Impact factor: 2.638

4.  Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.

Authors:  Ren-Yuan Bai; Dominic Esposito; Ada J Tam; Frank McCormick; Gregory J Riggins; D Wade Clapp; Verena Staedtke
Journal:  Gene Ther       Date:  2019-05-24       Impact factor: 5.250

Review 5.  Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: ANRIL Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients.

Authors:  Viviana Tritto; Luca Ferrari; Silvia Esposito; Paola Zuccotti; Donatella Bianchessi; Federica Natacci; Veronica Saletti; Marica Eoli; Paola Riva
Journal:  Genes (Basel)       Date:  2019-11-05       Impact factor: 4.096

Review 6.  CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.

Authors:  Jordan L Kohlmeyer; David J Gordon; Munir R Tanas; Varun Monga; Rebecca D Dodd; Dawn E Quelle
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

7.  Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature.

Authors:  Enrico Martin; Ivo S Muskens; J H Coert; Timothy R Smith; Marike L D Broekman
Journal:  Neurooncol Pract       Date:  2018-07-19

8.  Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1.

Authors:  Verena Staedtke; Tyler Gray-Bethke; Gregory J Riggins; Ren-Yuan Bai
Journal:  Genes (Basel)       Date:  2020-07-08       Impact factor: 4.096

9.  Malignant peripheral nerve sheath tumor of the nasal cavity and nasopharynx in a child: A case report.

Authors:  Qian Li; Hongguang Pan; Lan Li; Juan Cao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 10.  Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments.

Authors:  Anusha Amaravathi; Janet L Oblinger; D Bradley Welling; A Douglas Kinghorn; Long-Sheng Chang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.